America is slimming down — one shot at a time. The number of US adults turning to blockbuster GLP-1 drugs like Ozempic and Wegovy for weight loss has hit a record high, nearly quadrupling in just two ...

Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.

The launch of weight-loss pills is the hottest battle in pharma. So far, Eli Lilly is losing to rival Novo Nordisk. Since its ...

A child was shot Tuesday at a house in Milford Mill, SKY 11 reported. SKY 11 reported from over Selgrave Road between ...

Medicare will start the GLP-1 Bridge program July 1. Older adults who qualify for the weight-loss drugs will pay a monthly $50 copay.

A 14-year-old boy was shot multiple times early Sunday morning in the South Austin neighborhood on Chicago's West Side.

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

The global market for drugs like Ozempic, Wegovy, Mounjaro, and Zepbound was worth roughly $70 billion in 2025 and is projected by JP Morgan to exceed $200 billion by 2030.

The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them ...

New GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are likely to boost consumer demand, but employer-sponsored health insurance may not foot the bill.

So, in the week that the long-heralded Wegovy pill goes on sale in the UK, offering a non-injectable alternative way of ...

Don't wait until clinical milestones send their share prices soaring.